Cargando…

Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy

BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudulier, Christopher D., Tonti, Elena, James, Eddie, Kwok, William W., Larché, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817377/
https://www.ncbi.nlm.nih.gov/pubmed/31077596
http://dx.doi.org/10.1111/all.13867
_version_ 1783463413602582528
author Rudulier, Christopher D.
Tonti, Elena
James, Eddie
Kwok, William W.
Larché, Mark
author_facet Rudulier, Christopher D.
Tonti, Elena
James, Eddie
Kwok, William W.
Larché, Mark
author_sort Rudulier, Christopher D.
collection PubMed
description BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen‐specific (MHC II tetramer(+)) CD4(+) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat‐PAD on the frequency and functional phenotype of Fel d 1‐specific CD4(+) T cells. METHODS: Using before and after treatment samples from subjects enrolled in a randomized, double‐blind, placebo‐controlled trial of Cat‐PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1‐specific CD4(+) T cells. RESULTS: No statistically significant change in the frequency of Fel d 1‐specific CD4(+) T cells, nor in their expression of chemokine receptors or memory phenotype, was observed. However, a significant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups (P = 0.047). CONCLUSIONS: Peptide immunotherapy with Cat‐PAD does not significantly alter the frequency or phenotype of Fel d 1‐CD4(+) T cells, but may decrease their expression of CRTh2.
format Online
Article
Text
id pubmed-6817377
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68173772019-12-19 Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy Rudulier, Christopher D. Tonti, Elena James, Eddie Kwok, William W. Larché, Mark Allergy ORIGINAL ARTICLES BACKGROUND: Allergen immunotherapy using synthetic peptide T‐cell epitopes (Cat‐PAD) from the major cat allergen Fel d 1 has been shown, in allergen exposure studies, to significantly reduce symptoms of allergic rhinoconjunctivitis in cat‐allergic subjects. However, the immunological mechanisms underlying clinical benefit remain only partially understood. Since previous studies of whole allergen immunotherapy demonstrated a reduction in the frequency of allergen‐specific (MHC II tetramer(+)) CD4(+) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat‐PAD on the frequency and functional phenotype of Fel d 1‐specific CD4(+) T cells. METHODS: Using before and after treatment samples from subjects enrolled in a randomized, double‐blind, placebo‐controlled trial of Cat‐PAD, we employed Fel d 1 MHC II tetramers and flow cytometry to analyze the expression of chemokine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 and CCR7) on Fel d 1‐specific CD4(+) T cells. RESULTS: No statistically significant change in the frequency of Fel d 1‐specific CD4(+) T cells, nor in their expression of chemokine receptors or memory phenotype, was observed. However, a significant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups (P = 0.047). CONCLUSIONS: Peptide immunotherapy with Cat‐PAD does not significantly alter the frequency or phenotype of Fel d 1‐CD4(+) T cells, but may decrease their expression of CRTh2. John Wiley and Sons Inc. 2019-06-07 2019-11 /pmc/articles/PMC6817377/ /pubmed/31077596 http://dx.doi.org/10.1111/all.13867 Text en © 2019 The Authors. Allergy Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ORIGINAL ARTICLES
Rudulier, Christopher D.
Tonti, Elena
James, Eddie
Kwok, William W.
Larché, Mark
Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title_full Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title_fullStr Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title_full_unstemmed Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title_short Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
title_sort modulation of crth2 expression on allergen‐specific t cells following peptide immunotherapy
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817377/
https://www.ncbi.nlm.nih.gov/pubmed/31077596
http://dx.doi.org/10.1111/all.13867
work_keys_str_mv AT rudulierchristopherd modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy
AT tontielena modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy
AT jameseddie modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy
AT kwokwilliamw modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy
AT larchemark modulationofcrth2expressiononallergenspecifictcellsfollowingpeptideimmunotherapy